Zolmax Oak Street Health (NYSE:OSH Get Rating) and GeneDx (NASDAQ:WGS Get Rating) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk ...\n more…
Ticker Report Shares of Oak Street Health, Inc. (NYSE:OSH Get Rating) have received a consensus recommendation of Hold from the twenty ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ...\n more…
Ticker Report Oak Street Health (NYSE:OSH Get Rating) and GeneDx (NASDAQ:WGS Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, ...\n more…
Yahoo! Finance: News CVS Health posted higher revenue in the first quarter but downgraded its earnings projection for the year because of the impact of its biggest deals since the nearly $70 billion takeover of Aetna in 2018.\n more…
Forbes.com: Healthcare News CVS Health completed its acquistion of Oak Street Health for $10.6 billion in cash, adding a large network of doctor-staffed clinics primarily used by seniors.CVS Health completed its acquistion of Oak Street Health for $10.6 billion in cash, adding a large network of doctor-staffed clinics ...\n more…
Zolmax Oppenheimer Asset Management Inc. boosted its holdings in shares of Oak Street Health, Inc. (NYSE:OSH Get Rating) by 3.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,682 shares of the companys stock after ...\n more…